Immuno-oncology models

In vivo models for immuno-oncology research

In addition to general oncology study types and readouts, we offer a well-characterised portfolio of cell line-derived syngeneic immuno-oncology (IO) models, tailored to meet your research needs. Our models include comprehensive evaluation of major immune cell subsets, correlated with tumour progression. We utilise cell line-derived xenograft (CDX) syngeneic tumour models to study cancer therapies in the presence of a functional immune system. Additionally, we provide hPBMC/HSC/T-cell humanised models.

• Anti-tumor efficacy studies (including tolerability and exposure studies)
• Syngeneic CDX derived models
• Humanised mouse models (PBMCs, HSCs, T-cells)
• Pharmacokinetic (PK) and pharmacodynamic (PD) assessments
• In vivo imaging (bioluminescence, fluorescence)
• Cytokine and immuno-profiling employing spectral flow cytometry (>28 parameters)
• Single-cell RNA sequencing  
• Profiling of tumor-infiltrating lymphocytes and immuno-modulation effects
• Single and multi-color fluorescent and chromogenic staining
• In situ hybridization (RNAscope).